Feb 2012

Home >> Clinical Trials News Archive >> 2012 >> Feb 2012
FDA has issued the guidance, “Questions and Answers on Informed Consent Elements, 21 CFR § 50.25(c)."  This guidance is intended to help sponsors, investigators and Institutional Review Boards better understand the new informed consent requirement set forth in 21 CFR 50.25(c).
FDA issues draft guidance on biosimilar product development. The U.S. Food and Drug Administration today issued three draft guidance documents on biosimilar product development to assist industry in developing such products in the United States.
GE buys into Israeli maker of capsule to detect colon cancer. Check-Cap sells 5% stake to bring in strategic partner.
New record: 313 million shekels invested in clinical trials in Israeli hospitals during 2011. In the first place: clinical trials held in Ichilov hospital – 52 million shekels. Hebrew.
Israel ranked second most educated country in the world, study shows. According to OECD report, 78% of money invested in education is taken directly from public funds, while 45% of Israel’s population has completed post-secondary education.
Chief scientist launches new incentives promoting R&D in life science. The Office of the Chief Scientist (OCS) at the Israeli Ministry of Industry, Trade and Labor launched two new programs to help promote foreign investment in Israeli R&D in the Life Sciences sector.
The 2012 Ctrials association annual conference will be held on March 26 at Soraski health center in Tel Aviv (Hebrew).